ASP2151
Sponsors
Astellas Pharma Inc, Maruho Co., Ltd., Maruho Europe Limited, Astellas Pharma Europe Ltd.
Conditions
HealthyHealthy SubjectsHerpes GenitalisHerpes SimplexHerpes ZosterSafety of ASP2151
Phase 1
Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers
TerminatedNCT00870441
Start: 2009-03-31End: 2010-04-30Updated: 2013-02-28
Drug-Drug Interaction Study: ASP2151 and Ritonavir
CompletedNCT02223351
Start: 2014-09-30End: 2014-12-31Updated: 2019-02-27
Drug-Drug Interaction Study: ASP2151 and Montelukast
CompletedNCT02321748
Start: 2014-12-31End: 2015-04-30Updated: 2019-02-27
Drug-Drug Interaction Study: ASP2151 and Bupropion
CompletedNCT02369172
Start: 2015-02-28End: 2015-04-30Updated: 2019-02-21
Drug-Drug Interaction Study: ASP2151 and Midazolam
CompletedNCT02403635
Start: 2015-04-30End: 2015-05-31Updated: 2019-02-21
Study to Evaluate the Safety and Pharmacokinetics of ASP2151 in Healthy Non-elderly and Elderly Subjects
CompletedNCT02796118
Start: 2006-07-31End: 2006-10-31Updated: 2016-08-29
Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food
CompletedNCT02852876
Start: 2005-09-30End: 2005-12-31Updated: 2016-08-02
Phase 2
Phase 3
Phase III Study of ASP2151 in Herpes Simplex Patients
CompletedNCT01959295
Start: 2013-08-31End: 2015-04-27Updated: 2024-10-09
Phase III Study of ASP2151 in Herpes Zoster Patients
CompletedNCT01959841
Start: 2013-08-31End: 2015-07-10Updated: 2018-11-27
Open-label Study of ASP2151 in Herpes Simplex Patients
CompletedNCT02209324
Start: 2013-11-30End: 2015-08-20Updated: 2024-09-27